Chevallard Daniel R.

SEC source: 0001706176-26-000004 · wk-form4_1774874809.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,886

SEC source: 0001706176-26-000002 · wk-form4_1767734500.xml · derivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). "RSU Grant Date" shall mean January 2, 2026.

F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). "RSU Grant Date" shall mean January 2, 2026.

SEC source: 0001706176-26-000002 · wk-form4_1767734500.xml · derivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,200

Underlying: Common Stock · 84,200 shares

Expires 2036-01-01

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 2, 2026.

SEC source: 0001815776-25-000072 · wk-form4_1762562560.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,386

SEC source: 0001815776-25-000072 · wk-form4_1762562560.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,208

SEC source: 0001815776-25-000005 · wk-form4_1736806964.xml · derivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,444

Underlying: Common Stock · 70,444 shares

Expires 2035-01-08

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 9, 2025.

SEC source: 0001815776-24-000046 · wk-form4_1715803974.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,188

SEC source: 0001815776-24-000023 · wk-form4_1711413359.xml · derivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-03-20

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024.

SEC source: 0001209191-24-004825 · doc4.xml · derivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-03-12

F1 · derivative.exercise_date: 1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2024.

SEC source: 0001209191-24-004037 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,306

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 3,405 shares sold in the price range of $0.7316 to $0.7411 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-24-004037 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,444

Underlying: Common Stock · 6,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0001209191-24-004037 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-056842 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,822

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

SEC source: 0001209191-23-056842 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,333

Underlying: Common Stock · 6,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F3 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F3 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0001209191-23-056842 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-047665 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,653

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

SEC source: 0001209191-23-047665 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,222

Underlying: Common Stock · 6,888 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F3 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F3 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0001209191-23-047665 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-032707 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,110

Underlying: Common Stock · 6,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-23-032707 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,277

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 3,635 shares sold in the price range of $1.41 to $1.42 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-23-032707 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,912

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-019728 · doc4.xml · derivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-03-16

F1 · derivative.exercise_date: 1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2023.

SEC source: 0001209191-23-013854 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,023

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 3,599 shares sold in the price range of $1.68 to $1.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-23-013854 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,999

Underlying: Common Stock · 6,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-23-013854 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-058981 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,733

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 3,532 shares sold in the price range of $2.70 to $2.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-058981 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,888

Underlying: Common Stock · 6,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-058981 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-047948 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,376

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 3,655 shares sold in the price range of $4.01 to $4.13 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-047948 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,777

Underlying: Common Stock · 6,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-047948 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,031

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-032665 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,142

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 3,596 shares sold in the price range of $1.90 to $1.95 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-032665 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,666

Underlying: Common Stock · 6,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-032665 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,738

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-020080 · doc4.xml · derivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2032-03-17

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date.

SEC source: 0001209191-22-014438 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,849

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 3,998 shares sold in the price range of $2.7101 to $2.84 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014438 · doc4.xml · derivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,555

Underlying: Common Stock · 6,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-014438 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-21-067045 · doc4.xml · nonDerivative · entry 3

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,958

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F4 · price: Represents the weighted average share price of an aggregate total of 4,325 shares sold in the price range of $4.62 to $5.34 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-067045 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,283

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 3,254 shares sold in the price range of $4.7150 to $5.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-067045 · doc4.xml · derivative · entry 4

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,444

Underlying: Common Stock · 13,777 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F5 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F5 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-21-067045 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,537

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-21-058099 · doc4.xml · derivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,817

Underlying: Common Stock · 10,000 shares

Expires 2029-07-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of July 30, 2019 (the "Vesting Commencement Date") and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, the last day of the month), subject to the reporting person continuing to be a Service Provider in accordance with Viracta Subsidiary, Inc.'s 2016 Equity Incentive Plan (the "Plan") through each such date.

SEC source: 0001209191-21-058099 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-036907 · doc4.xml · derivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,817

Underlying: Common Stock · 12,000 shares

Expires 2029-07-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of July 30, 2019 (the "Vesting Commencement Date") and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, the last day of the month), subject to the reporting person continuing to be a Service Provider in accordance with Viracta Subsidiary, Inc.'s 2016 Equity Incentive Plan (the "Plan") through each such date.

SEC source: 0001209191-21-036907 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-023636 · doc4.xml · derivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · CFO and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,912

Underlying: Common Stock · 78,912 shares

Expires 2031-03-26

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 26, 2021 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date.

SEC source: 0001209191-19-040500 · doc4.xml · nonDerivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,870

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 2/5/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.

SEC source: 0001209191-19-030506 · doc4.xml · nonDerivative · entry 2

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,539

F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 5/14/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.

SEC source: 0001209191-19-030569 · doc4a.xml · derivative · entry 1

Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2029-02-04

F1 · derivative.exercise_date: On February 5, 2019, the reporting person was granted an option to purchase the number of shares of common stock set forth in Box 5. The option vests only upon the achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the option. Upon achievement of the milestone, 50% of the options subject to the milestone immediately vest, with the remaining options vesting in 24 equal monthly installments following the vesting commencement date.

F2 · balance_after: The original Form 4, filed on May 16, 2019, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the number of shares reported in Boxes 7 and 9. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the reported transaction was incorrectly reported.